ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
17 juil. 2023 07h38 HE | ZyVersa Therapeutics
Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development...
EnteroBiotix-Logo-R-Colour-WB-RGB.png
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy
28 mars 2023 03h00 HE | EnteroBiotix
GLASGOW, United Kingdom, March 28, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biotechnology company focussed on developing best-in-class full-spectrum microbiome...
BioVie Logo.jpg
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
06 févr. 2019 08h00 HE | BioVie Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today...
Ocera Completes Enro
Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
07 déc. 2016 09h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), today announced it has completed enrollment in its Phase 2b STOP-HE...
Ocera to Present at
Ocera to Present at the Stifel 2016 Healthcare Conference
09 nov. 2016 09h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
Ocera to Present at
Ocera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference
20 sept. 2016 09h10 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at
Ocera to Present at the 15th Annual Needham Healthcare Conference
05 avr. 2016 16h25 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 05, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera to Present at
Ocera to Present at BIO Investor Forum 2015
13 oct. 2015 16h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Ocera Therapeutics S
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and Silicon Valley Bank
30 juil. 2015 16h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc.  (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Tranzyme Pharma Anno
Tranzyme Pharma Announces First Quarter 2013 Financial Results
09 mai 2013 16h30 HE | Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel,...